Another finding by Bugara et al. showed that the downregulation of PHLDA1 in IMR-32 neuroblastoma cells does not affect the response to treatment with lapatinib and another inhibitor of EGFR, gefitinib (Bugara et al. 2024). Here, PHLDA1 is linked to neuroblastoma.